Five Houston research centers have received funds from the Cancer Prevention and Research Institute of Texas in its most recent round of grants. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

The Cancer Prevention and Research Institute of Texas has again granted millions to Texas institutions. Across the state, cancer-fighting scientists have received 55 new grants totaling over $78 million.

Five Houston-area institutions — Baylor College of Medicine, the University of Houston, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Houston, and the The University of Texas MD Anderson Cancer Center — have received around $30 million of that grand total.

"These awards reflect CPRIT's established priorities to invest in childhood cancer research, address population and geographic disparities, and recruit top cancer research talent to our academic institutions," says Wayne Roberts, CPRIT CEO, in a news release. "I'm excited about all the awardees, particularly those in San Antonio, a region that continues expand their cancer research and prevention prowess. San Antonio is poised to have an even greater impact across the Texas cancer-fighting ecosystem."

Four grants went to new companies that are bringing new technologies to the market. Two companies with a presence in Houston — Asylia Therapeutics and Barricade Therapeutics Corp. — received grants in this category.

Last fall, CPRIT gave out nearly $136 million to Texas researchers, and, to date, the organization has granted $2.49 billion to Texas research institutions and organizations.

Here's what recent grants were made to Houston institutions.

Baylor College of Medicine

  • $900,000 granted for Feng Yang's research in targeting AKT signaling in MAPK4-high Triple Negative Breast Cancer (Individual Investigator Award)
  • $897,527 Hyun-Sung Lee's research for Spatial Profiling of Tumor-Immune Microenvironment by Multiplexed Single Cell Imaging Mass Cytometry (Individual Investigator Award)
  • $899,847 for Joshua Wythe's research in targeting Endothelial Transcriptional Networks in GBM (Individual Investigator Award)

University of Houston

  • $890,502 for Matthew Gallagher's research in Transdiagnostic Cognitive Behavioral Therapy for Smokers With Anxiety and Depression (Individual Investigator Research Award for Prevention and Early Detection)
  • $299,953 for Lorraine Reitzel's research in Taking Texas Tobacco Free Through a Sustainable Education/Training Program Designed for Personnel Addressing Tobacco Control in Behavioral Health Settings (Dissemination of CPRIT-Funded Cancer Control Interventions Award)

The University of Texas Medical Branch at Galveston

  • $1,993,096 for Abbey Berenson's research in maximizing opportunities for HPV vaccination in medically underserved counties of Southeast Texas (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)

The University of Texas Health Science Center at Houston

  • $900,000 for Melissa Aldrich's research on "Can Microsurgeries Cure Lymphedema? An Objective Assessment" (Individual Investigator Award)
  • $900,000 for John Hancock's research in KRAS Spatiotemporal Dynamics: Novel Therapeutic Targets (Individual Investigator Award)
  • $900,000 for Nami McCarty's research in targeting Multiple Myeloma Stem Cell Niche (Individual Investigator Award)
  • $1.96 million for Paula Cuccaro's research in Expanding "All for Them": A comprehensive school-based approach to increase HPV vaccination through public schools (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)

The University of Texas MD Anderson Cancer Center

  • $900,000 for Laurence Court's research in Artificial Intelligence for the Peer Review of Radiation Therapy Treatments
  • $900,000 for John deGroot's research in targeting MEK in EGFR-Amplified Glioblastoma (Individual Investigator Award)
  • $900,000 for Don Gibbons's research in Investigating the Role ofCD38 as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer (Individual Investigator Award)
  • $900,000 for John Heymach's research in Molecular Features Impacting Drug Resistance in Atypical EGFR Exon 18 and Exon 20 Mutant NSCLC and the Development of Novel Mutant- Selective Inhibitors (Individual Investigator Award)
  • $900,000 for Zhen Fan's research in Development of a Novel Strategy for Tumor Delivery of MHC-I-Compatible Peptides for Cancer Immunotherapy (Individual Investigator Award)
  • $900,000 for Jin Seon Im's research in off the shelf, Cord-Derived iNK T cells Engineered to Prevent GVHD and Relapse After Hematopoietic Stem Cell Transplantation (Individual Investigator Award)
  • $900,000 for Jae-il Park's research in CRAD Tumor Suppressor and Mucinous Adenocarcinoma (Individual Investigator Award)
  • $900,000 for Helen Piwnica-Worms's research in Single-Cell Evaluation to Identify Tumor-stroma Niches Driving the Transition from In Situ to Invasive Breast Cancer (Individual Investigator Award)
  • $898,872 for Kunal Rai's research in Heterogeneity of Enhancer Patterns in Colorectal Cancers- Mechanisms and Therapy (Individual Investigator Award)
  • $900,000 for Ferdinandos Skoulidis's research in Elucidating Aberrant Splicing-Induced Immune Pathway Activation in RBMl0-Deficient KRAS-Mutant NSCLC and Harnessing Its Potential for Precision Immunotherapy (Individual Investigator Award)
  • $887,713 for Konstantin Sokolov's research in High-Sensitivity 19F MRI for Clinically Translatable Imaging of Adoptive NK Cell Brain Tumor Therapy (Individual Investigator Award)
  • $900,000 for Liuqing Yang's research in Adipocyte-Producing Noncoding RNA Promotes Liver Cancer Immunoresistance (Individual Investigator Award)
  • $1.44 million for Eugenie Kleinerman's research in Doxorubicin-Induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and AYA Sarcoma Patients for Evaluating Exercise Interventions (Individual Investigator Award for Cancer in Children and Adolescents)
  • $2.4 million for Arvind Dasari's research in Circulating Tumor DNA- Defined Minimal Residual Disease in Colorectal Cancer (Individual Investigator Research Award for Clinical Translation)
  • Targeting Alterations of the NOTCH! Pathway in Head and Neck Squamous Cell Carcinoma (HNSCC)(Faye Johnson) - $1.2 million (Individual Investigator Research Award for Clinical Translation)
  • $2.07 million for Florencia McAllister's research in Modulating the Gut- Tumor Microbial Axis to Reverse Pancreatic Cancer Immunosuooression (Individual Investigator Research Award for Clinical Translation)
  • $2 million to recruit Eric Smith, MD, PhD, to The University of Texas MD Anderson Cancer Center from Memorial Sloan Kettering Cancer Center (Recruitment of First-Time, Tenure-Track Faculty Members Award)
  • $2 million for Karen Basen-Engquist's research in Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)


Seed Awards for Product Development Research

  • Houston and Boston-based Asylia Therapeutics's Jeno Gyuris was granted $3 million for its development of a Novel Approach to Cancer Immunotherapy by Targeting Extracellular Tumor- derived HSP70 to Dendritic Cells
  • Houston-based Barricade Therapeutics Corp.'s Neil Thapar was granted $3 million for its development of a First-In-Class Small Molecule, TASIN, for Targeting Truncated APC Mutations for the Treatment of Colorectal Cancer (CRC)
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

University of Houston med school secures full accreditation

med school milestone

The University of Houston’s Tilman J. Fertitta Family College of Medicine has officially earned full accreditation after launching six years ago.

The designation comes from the Liaison Committee on Medical Education, which granted UH the maximum five-year review period available to a new medical school. To achieve the status, the committee reviewed the Fertitta College of Medicine's facilities, faculty and student outcomes, and curriculum to ensure the college met the highest standards in medical education.

“Full accreditation is not the finish line — it’s the foundation for everything we hope to accomplish in the years ahead,” Dr. Jonathan McCullers, vice president for health affairs at UH and dean of the Fertitta College of Medicine, said in a news release. “It strengthens our ability to attract outstanding students and faculty, expand our partnerships and prepare the next generation of physicians.”

Fertitta College of Medicine has graduated three classes of physicians, and every graduate from its most recent class secured a residency position. Enrollment has expanded from 30 students in its inaugural class to 65 students in its current class.

According to UH, about 70 percent of graduates have chosen to remain in Texas for further training, which is key to addressing the estimated 10,000 doctors needed to meet growing needs.

Fertitta College of Medicine opened for its first students in 2020, and now joins 14 other Texas schools as a fully LCME-accredited medical school. It also joins UTHealth Houston's McGovern Medical School and Baylor College of Medicine as one of three Houston-based LCME-accredited campuses.

The news comes after UH launched its health enterprise initiative, UH Health, in July and broke ground on its $77.5 million Medical Research Building next to the Fertitta College of Medicine last month.

“Building a medical school from the ground up is an extraordinary undertaking, and this milestone reflects the dedication of everyone who helped make it happen,” Dr. Stephen Scott, vice dean for education at the Fertitta College of Medicine, added in the release. “From developing an innovative curriculum to establishing the systems and partnerships that support our students, this has been a true team effort.”

Woodlands startup Mavria raises $130M to mass-produce AI data centers

seed funding

The Woodlands-based Mavria, which mass-produces factory-built modular AI data centers, just emerged from stealth mode with $130 million in funding at a $1 billion valuation.

Mavria raised the money in pre-seed and seed rounds led by Paradigm, an investment firm that concentrates on early-stage startups developing “pioneer” technology. Participants in the funding rounds include AMP PBC, Critical Frontier, Dream Ventures and Liquid 2 Ventures, co-founded by former NFL quarterback Joe Montana.

The company’s inaugural product, Terrain, is a prefabricated data center designed for AI labs, cloud computing providers and data center developers. Mavria says its platform avoids ground-up construction, delivering infrastructure more quickly and at a lower cost.

Mavria tells the Wall Street Journal that the first Terrain unit is being built at a Houston-area factory. The 5-megawatt Terrain system features power distribution, direct liquid cooling, controls and server racks.

“America sets the pace at the intelligence frontier. But the race is moving from the lab into the physical world,” Adam Blake, co-founder and CEO of Mavria, wrote in a blog post.

“Intelligence needs data centers. Data centers need power. Power needs factories, equipment, supply chains, and skilled workers, but much of that infrastructure is still built one custom project at a time, on timelines measured in years.”

Blake and Mavria’s two other co-founders, Nick Poradek and Seth Cohen, most recently worked at the U.S. Department of Energy. There, they focused on reforming the nuclear power sector.

From start to finish, it can take roughly three to six years to build a data center at an estimated cost of $10 million to $37 million per megawatt. Based on those figures, a 100-megawatt data center might cost as much as $3.7 billion.

Here are brief bios of Blake, Poradek and Cohen, who co-founded Mavria in May.

Adam Blake

Blake most recently was a senior advisor to U.S. Energy Secretary Chris Wright. He is co-founder and former CEO of Zego, a provider of energy management technology for property managers. Zego spun out from Brightergy, a commercial solar company. Blake is founder and former CEO of Brightergy.

Nick Poradek

Poradek, chief operating officer at Mavria, was also an advisor to the U.S. energy secretary. He is founder and former CEO of Spring-based Edera Energy, co-founder of The Woodlands-based craft-ice brand Clarity Ice, and founder and former CEO of The Woodlands-based Edera Capital. Poradek sold Edera Energy, a manufacturer of oilfield equipment, to Liberty Energy, a fracking company. Wright is Liberty’s founder and former chairman and CEO.

Seth Cohen

Cohen, chief strategy officer and chief legal officer at Mavria, was head of nuclear law and policy at the Department of Energy. He is also a former NASA advisor and a former attorney at Kirkland & Ellis.

“We believe in rapidly deploying infrastructure as a product, rather than custom-building every project,” Blake said. “We’re bringing together engineering, manufacturing, supply chains and capital so that every project makes us better at delivering the next.”